Passage Bio stock gains 1.01 percent as Remix deal advances

Published on 09/24/2026 at 13:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Passage Bio stock reached USD 5.00 on September 23, 2026, while the amended Remix transaction provides for 27,012,093 new shares. Q2 net loss rose 16.7 percent year over year.

Passage Bio stock, biotechnology, Remix merger, private financing, Nasdaq, Illustration mit AI erstellt.

Passage Bio stock (ISIN US7027122099) gained 1.01 percent to USD 5.00 on Nasdaq on September 23, 2026, giving the clinical-stage genetic medicines company a market capitalization of USD 16,064,050. The move came as its planned combination with Remix Therapeutics advanced through amended transaction documents.

Remix deal sets share count

According to Stock Titan, Passage Bio expects to issue 27,012,093 common shares to Remix equityholders under an assumed exchange ratio of 0.1728. The September 21, 2026 filing also states that the combined company is expected to trade on Nasdaq under the symbol RMTX after closing.

The structure would rename Passage Bio as Remix Therapeutics, Inc. and leave Remix as a wholly owned subsidiary. For current PASG holders, the central valuation issue is the scale of the new share issuance relative to the existing company, rather than a routine pipeline update.

Private financing adds USD 70.0 million

The amended agreements provide for a concurrent private financing of USD 70.0 million. Investors may purchase Remix common stock at USD 1.3861 per share or pre-funded warrants at USD 1.3860, according to The Globe and Mail on September 2, 2026. The transaction has an outside closing date of December 24, 2026.

The financing terms sit well below the September 23 market price of USD 5.00, but the securities are tied to the merger structure and are not a direct public-market quote for PASG. That distinction matters because the planned financing and the share issuance can alter ownership proportions after completion.

Loss widens year over year

Passage Bio reported a net loss of USD 7.8 million in Q2 2026, an increase of 16.7 percent from the same quarter a year earlier, according to Stock Titan. The company is a clinical-stage biotechnology business focused on genetic medicines for neurodegenerative diseases, including the PBFT02 product candidate, according to its investor site.

Stock stays above yearly low

Passage Bio stock stood at USD 5.00 on Nasdaq on September 23, 2026, with a 52-week range of USD 3.29 to USD 20.00. The 1.01 percent daily gain places the stock USD 1.71 above its yearly low and USD 15.00 below its yearly high, keeping the merger structure and planned share count central to the market reading.